Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Good Manufacturing Practices in Malaysia in 2026: NPRA GMP Inspection Guide

Learn how Malaysia GMP guidelines and NPRA GMP inspections align with PIC/S GMP requirements. This guide explains pharmaceutical quality systems, inspection priorities, common findings, CAPA expectations, and practical strategies to improve GMP compliance and inspection readiness.
  • Blog, Quality Management System
NPRA GMP inspection in a pharmaceutical manufacturing Malaysia facility following PIC/S GMP requirements and pharmaceutical quality system standards

One Leadership Change, Hidden GMP Risks; Why Quality Systems Start to Fail

Leadership experts in the healthcare sector have warned that organizational strategies often become vulnerable during executive transitions when they rely on individual leaders instead of institutional governance. Although the discussion originated from healthcare leadership, its implications extend directly to Pharmaceutical
  • News
One Leadership Change, Hidden GMP Risks; Why Quality Systems Start to Fail

FDA Approves Subcutaneous Isatuximab; Why PK Bridging May Redefine Future Biologic Approvals

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous formulation of isatuximab-irfc (Sarclisa Escena) for three multiple myeloma treatment regimens, expanding an anti-CD38 therapy that was previously available only as an intravenous infusion. While the approval offers patients
  • News
FDA Approves Subcutaneous Isatuximab; Why PK Bridging May Redefine Future Biologic Approvals

FDA Freezes CRL Transparency; What Changes for Pharma Compliance

The FDA has paused the public release of new Complete Response Letters (CRLs) while reviewing a citizen petition that challenges the legal basis of the disclosure program. The decision temporarily interrupts one of the agency’s most significant transparency initiatives and
  • News
FDA Freezes CRL Transparency; What Changes for Pharma Compliance

MindRank Secures $52M; AI-Designed Drugs Move Beyond Discovery

Artificial intelligence has taken another step from research into regulated drug development. Chinese biotech MindRank has secured $52 million in Series B funding to advance its AI-powered drug discovery platform and accelerate the clinical development of its oral GLP-1 receptor
  • News
MindRank Secures $52M; AI-Designed Drugs Move Beyond Discovery

FDA Speeds Up IND Reviews; Experts Say Protocol Design Still Drives Success

The U.S. Department of Health and Human Services (HHS) has introduced Operation Trialblazer, a multi-agency initiative designed to accelerate early-stage drug development and modernize clinical research across the United States. Working alongside the FDA and the National Institutes of Health
  • News
FDA Speeds Up IND Reviews; Experts Say Protocol Design Still Drives Success

Good Manufacturing Practices in Australia in 2026: TGA GMP Inspection Guide

Understand how TGA GMP inspections work in Australia, explore official GMP guidance PDFs, review common inspection findings, and use a practical GMP compliance checklist to strengthen pharmaceutical quality systems and improve inspection readiness before your next regulatory audit.
  • Blog, Quality Management System
Illustration of a pharmaceutical manufacturing facility showing TGA GMP inspection activities, pharmaceutical quality system controls, and GMP inspection readiness based on Australia GMP guidelines.

FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

The U.S. Food and Drug Administration (FDA) has temporarily paused the public release of Complete Response Letters (CRLs). The agency made the decision after an unnamed pharmaceutical company challenged the policy over confidentiality concerns. The move temporarily suspends one of
  • News
FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

China Drives Pharma Innovation; Regulatory Scrutiny Is Rising Alongside It

AstraZeneca and GSK have announced separate agreements with China's Sino Biopharm, reinforcing a growing trend of cross-border pharmaceutical partnerships. AstraZeneca licensed an investigational respiratory medicine, while GSK expanded its commercial collaboration in China. The announcements come as regulators increasingly examine
  • News
China Drives Pharma Innovation; Regulatory Scrutiny Is Rising Alongside It

Good Manufacturing Practices in Canada in 2026: Health Canada GMP Inspection Guide

Learn how Health Canada GMP inspections evaluate pharmaceutical manufacturers, explore official guidance documents, review common inspection findings, and use practical checklists to strengthen compliance and prepare for successful Drug Establishment Licence inspections.
  • Blog, Quality Management System
Pharmaceutical quality specialist reviewing manufacturing compliance during a Health Canada inspection, illustrating GMP in Canada, GUI 0001 requirements, and Drug Establishment Licence Canada readiness.